Companion Diagnostic Tests in Oncology Market Size is Set to Achieve USD 17.0 Billion by 2034, with 9.5% CAGR: Transparency Market Research Inc.
09. September 2024 20:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- The global companion diagnostic tests in oncology market (الاختبارات التشخيصية المصاحبة...
[Latest] Global Non-Small-Cell Lung Cancer Drug Market Size/Share Worth USD 68,888.6 Million by 2033 at a 8.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
21. Mai 2024 03:30 ET
|
Custom Market Insights
Austin, TX, USA, May 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Non-Small-Cell Lung Cancer Drug Market Size, Trends and Insights By Cancer Type...
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
03. November 2023 10:46 ET
|
Travere Therapeutics, Inc.
“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape ..."
Point of Care Molecular Diagnostics Market Worth $5.38 Billion by 2028 - Exclusive Report by The Insight Partners
30. Oktober 2023 05:27 ET
|
The Insight Partners
Pune, India, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Point-of-care molecular diagnostics include portable devices, and assays & kits used to detect and diagnose diseases in human samples, such as...
Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference
11. Oktober 2023 12:00 ET
|
Quanta Therapeutics, Inc.
The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.
EGFR Tests Market Report: Quantitative Trends, Regulatory Dynamics, and Future Projections
06. September 2023 05:53 ET
|
Research and Markets
Dublin, Sept. 06, 2023 (GLOBE NEWSWIRE) -- The "EGFR Tests Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and...
Dignity Health St. Joseph’s Hospital and Medical Center launches new initiative to address health disparities of African Americans with chronic kidney disease
27. Februar 2023 16:08 ET
|
Dignity Health St. Joseph's Hospital and Medical Center
PHOENIX, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Dignity Health St. Joseph’s Hospital and Medical Center has launched a new initiative to address race-based algorithms in early diagnosis of chronic kidney...
Liquid Biopsy Global Market Report 2022: Increased Government Funding for Cancer Detection Drives Growth
15. November 2022 08:33 ET
|
Research and Markets
Dublin, Nov. 15, 2022 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Global Market Report 2022, By Product, By End User, By Clinical Application" report has been added to ResearchAndMarkets.com's offering....
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
16. Dezember 2021 06:30 ET
|
Cullinan Oncology, Inc.
CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in...
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
13. Dezember 2021 07:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...